Clinical trials: Hemostatic Disorders
Acute Myeloid Leukemia, Acute Leukemia
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma
- Trial name
- NCT01499147
- Testing
- fludarabine/busulfan, fludarabine/ melphalan, ATG
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Illinois Chicago
Graft Versus Host Disease, Leukemia
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
RATIONALE: Giving monoclonal antibody therapy, radioimmunotherapy, and chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00577278
- Testing
- rituximab, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in…
- Trial name
- NCT02076009
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- 145 sites in United States, Australia and 16 more
- Volunteers
- 569 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Lymphoma
Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma
Primary Objectives: 1. To determine the efficacy of administering multiple doses of intravenous (i.v.) busulfan at a dose of 130 mg/m2, to yield a systemic plasma drug exposure represented by a daily area under the plasma…
- Trial name
- NCT00427765
- Testing
- Busulfan, Melphalan
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00589563
- Testing
- anti-thymocyte globulin, cyclophosphamide, etoposide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying how well rituximab works in preventing acute graft-versus-host disease (GVHD) in patients undergoing a donor stem cell transplant for hematologic cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT01044745
- Testing
- rituximab, mycophenolate mofetil, tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
Stage II Multiple Myeloma, Stage III Multiple Myeloma
Aflibercept for Relapsed Multiple Myeloma
This phase II trial is studying the side effects and how well aflibercept works in treating patients with stage II or stage III multiple myeloma that has relapsed or not responded to previous treatment.
- Trial name
- NCT00437034
- Testing
- aflibercept
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose and effectiveness of the study drug (CC-4047) Alone Or in Combination With Low-dose Dexamethasone as treatment for patients with relapsed and refractory…
- Trial name
- NCT00833833
- Testing
- Pomalidomide, Dexamethasone, Aspirin
- Where
- 19 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Celgene Corporation
Multiple Myeloma
A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
This is a multi-centre, single-arm treatment study combining lenalidomide plus high dose dexamethasone. Subjects who qualify for participation will receive lenalidomide plus high dose dexamethasone in 4 week cycles.
- Trial name
- NCT00420849
- Testing
- Lenalidomide, Dexamethasone
- Where
- 5 sites in Australia, Austria and 3 more
- Volunteers
- 587 people
- Sponsor
- Celgene Corporation
Multiple Myeloma
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational combination of drugs.
- Trial name
- RVD Lite (NCT01782963)
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort…
- Trial name
- NCT07217184
- Testing
- Belantamab mafodotin, Isatuximab
- Where
- 19 sites in United States, Australia and 9 more
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
The purpose of this research study is to determine the safety of CCI-779 (Temsirolimus) and bortezomib (Velcade), and the highest dose of this drug that can be given to people safely.
- Trial name
- NCT00483262
- Testing
- CCI-779, Bortezomib
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in patients with…
- Trial name
- EVOLUTION (NCT00507442)
- Testing
- VELCADE (bortezomib), dexamethasone, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 158 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
This was a multicenter, open-label, randomized phase II study which were to enroll 112 newly diagnosed symptomatic multiple myeloma patients in a 1:1 fashion.
- Trial name
- PANORAMA4 (NCT02720510)
- Testing
- Revlimid, Velcade, dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, Recurrent Multiple Myeloma
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
This phase II trial studies the effect of immunomodulatory drug(s) in combination with a corticosteroid drug in treating patients with multiple myeloma or smoldering multiple myeloma.
- Conditions
- Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
- Trial name
- NCT05288062
- Testing
- Bone Marrow Biopsy, Dexamethasone, Lenalidomide
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
This was a randomized, controlled, open-label, Phase 3 multicenter study which enrolled patients with Relapsed-Refractory Multiple Myeloma (RRMM) who were either double refractory to an Immunomodulatory Drug (IMiD) and a…
- Trial name
- LIGHTHOUSE (NCT04649060)
- Testing
- Melflufen, Dexamethasone, Daratumumab
- Where
- 26 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 54 people
- Sponsor
- Oncopeptides AB
Multiple Myeloma
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
The patients are being offered a stem cell transplant. Stem cells are very early blood cells. They have not yet matured to become red or white blood cells or platelets.
- Trial name
- NCT01131169
- Testing
- busulfan, melphalan and fludarabine
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Chronic Kidney Disease
Optimising Renal Outcome in Myeloma Renal Failure
The purpose of this study is to compare the effectiveness of bortezomib versus thalidomide in reducing free light chains in the blood of myeloma patients.
- Trial name
- OPTIMAL (NCT02424851)
- Testing
- Bortezomib, Thalidomide, Bendamustine
- Where
- 9 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Oxford University Hospitals NHS Trust
Bleeding Peptic Ulcer
High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
To describe the rate of clinically significant rebleeding during 72 hours continuous i.v. infusion of high dose esomeprazole Na in patients in China with primary successful endoscopic haemostatic therapy of a bleeding peptic…
- Trial name
- NCT01757275
- Testing
- Esomeprazole Na, Cimetidine, Esomeprazole Mg
- Where
- 12 sites in China
- Volunteers
- 239 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.